1 **TEMPORAL TRENDS AND TRANSMISSION DYNAMICS OF PRE-TREATMENT HIV-1**

2 **DRUG RESISTANCE WITHIN AND BETWEEN RISK GROUPS IN KENYA, 1986-2020.**

3

4 George M. Nduva^{1,2*}, Frederick Otieno³, Joshua Kimani^{4,5}, Yiakon Sein², Dawit A. Arimide¹, Lyle R. 5 McKinnon^{4,5,6}, Francois Cholette^{5,7}, Morris K. Lawrence⁸, Maxwell Majiwa⁹, Moses Masika¹⁰, 6 Gaudensia Mutua¹⁰, Omu Anzala¹⁰, Susan M. Graham^{2,11}, Larry Gelmon^{4,5}, Matt A. Price^{12,13}, Adrian 7 D. Smith¹⁵, Robert C. Bailey^{3,13}, Patrik Medstrand¹, Eduard J. Sanders^{2,15#}, Joakim Esbjörnsson^{1,15#}, 8 and Amin S. Hassan^{1,2#}*.

9

10 *** Equal contribution as senior authors

11

12 ¹Lund University, Lund, Sweden; ²KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya; ³Nyanza Reproductive Health Society, Kisumu, Kenya; ⁴University of Nairobi, Nairobi, Kenya; ⁵University of Manitoba, Winnipeg, Canada; ⁶Centre for the AIDS Programme of Research in South 15 Africa (CAPRISA), South Africa; ⁷National Microbiology Laboratory at the JC Wilt Infectious 16 Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada; ⁸ Pwani University, 17 Kilifi, Kenya; ⁹KEMRI/Center for Global Health Research, Kisumu, Kenya; ¹⁰KAVI Institute of 18 Clinical Research, University of Nairobi, Nairobi, Kenya; ¹¹University of Washington, Seattle, USA; 19 ¹²IAVI, New York, USA; ¹³University of California, San Francisco, USA; ¹⁴University of Illinois at 20 Chicago, USA; and ¹⁵ University of Oxford, Oxford, United Kingdom.

21

22 ***Corresponding Authors:**

1

2 **Short title:** Pre-treatment HIV-1 drug resistance in Kenya

1 **Summary:**

- 2 Compared to the heterosexual population, key populations had higher levels of pre-treatment
- 3 HIV-1 drug resistance (HIVDR). Propagation of HIVDR was risk-group exclusive.
- 4 Introduction of integrase inhibitors abrogated propagation of reverse transcriptase inhibitors
- 5 mutations among the heterosexual, but not key populations.
- 6
- 7 **Keywords:** HIV-1, pre-treatment drug resistance; transmission clusters; risk groups; Kenya.
- 8

1 **ABSTRACT**

2

3 **Background:** Evidence on the distribution of pre-treatment HIV-1 drug resistance (HIVDR) by risk 4 groups is limited in Africa. We assessed prevalence, trends, and transmission dynamics of pre-5 treatment HIVDR within-and-between men who have sex with men (MSM), people who inject drugs 6 (PWID), female sex workers (FSW), heterosexuals (HET), and children infected perinatally in Kenya. 7 **Methods:** HIV-1 partial *pol* sequences from antiretroviral- naïve samples collected between 1986- 8 2020 were used. Pre-treatment RTI, PI and INSTI mutations were assessed using the Stanford 9 HIVDR database. Phylogenetics methods were used to determine and date transmission clusters. 10 **Results:** Of 3567 sequences analysed*,* 550 (15.4%, 95% CI: 14.2-16.6) had at least one pre-treatment 11 HIVDR mutation, which was most prevalent amongst children (41.3%), followed by PWID (31.0%), 12 MSM (19.9%), FSW (15.1%) and HET (13.9%). No INSTI resistance mutations were detected. 13 Among HET, pre-treatment HIVDR increased from 6.6% in 1986-2005 to 20.2% in 2011-2015 but 14 dropped to 6.5% in 2016-2020. Overall, 22 clusters with shared pre-treatment HIVDR mutations were 15 identified. The largest was a K103N mutation cluster involving 16 MSM sequences sampled between 16 2010-2017, with an estimated tMRCA of 2005 (HPD, 2000-2008). This lineage had a growth 17 rate=0.1/year and R_0 =1.1, indicating propagation over 12 years among ART-naïve MSM in Kenya. 18 **Conclusions:** Compared to HET, children and key populations had higher levels of pre-treatment 19 HIVDR. Introduction of INSTIs after 2016 may have reversed the increase in pre-treatment RTI 20 mutations in Kenya. Continued surveillance of HIVDR, with a particular focus on children and key 21 populations, is warranted to inform treatment strategies in Kenya.

1 **INTRODUCTION**

2

3 By the end of 2020, an estimated 30 million individuals were receiving antiretroviral therapy (ART) 4 globally¹. The scale-up of ART has substantially reduced new HIV-1 infections, vertical 5 transmissions, HIV-1 related mortality, and improved life expectancy for millions of people with HIV $(6 \text{FWHIV})^{1.3}$. However, widespread use of ART at the population-level has been associated with the 7 emergence of HIV-1 drug resistance (HIVDR), and the transmission of drug resistant viruses that can 8 . compromise therapy outcomes^{$4-9$}.

9 The World Health Organization (WHO) recommends routine nationally representative HIVDR 10 surveys to inform treatment strategies^{10,11}. Increasing levels of pre-treatment HIVDR to non-11 nucleoside reverse transcriptase inhibitors (NNRTIs) has been recognized as a problem for many 12 years, especially in low and middle-income countries (LMIC) where virologic monitoring of patients 13 on ART is sub-optimal¹²⁻¹⁵. Out of concern for treatment failure in the setting of increasing NNRTI 14 resistance and poor tolerability of PIs, WHO has prompted a switch to INSTIs with a high genetic 15 barrier as first-line regimens in LMIC settings – and Dolutegravir (DTG) is now widely adopted in 16 first-line regimen both for treatment naïve and experienced PWHIV $16,17$. However, it is not clear if the 17 switch to DTG-based regimens, which came into effect in LMIC settings in 2016, may have impacted 18 emergence and circulation of NNRTI resistant strains and this warrants further evaluation.

19 Further, key populations including men who have sex with men (MSM), people who inject drugs 20 (PWID), female sex workers (FSW), transgender people, and people in prisons, are disproportionately 21 impacted by HIV-1 in Sub-Saharan Africa. Transmission from key population individuals is thought 22 to contribute disproportionately to Africa's generalized HIV-1 epidemic^{18,19}. We previously 23 demonstrated that the majority of HIV-1 transmissions in Kenya occur within distinct risk groups, $20-22$ 24 and, although infrequent, HIV-1 transmission from HET to key populations is more common than 25 vice-versa²². However, it remains unknown whether there is differential transmission of HIVDR 26 mutations within and between HET and key populations in Kenya. This study aimed to describe 27 prevalence, temporal trends, and transmission linkages of pre-treatment HIVDR mutations within and 28 between risk groups in Kenya.

1 **METHODS**

2

3 **Study population**

4 HIV-1 partial *pol* sequences from Kenya were either newly generated from archived plasma samples 5 (henceforth referred as newly generated) or retrieved from the Los Alamos HIV-1 sequence database 6 (henceforth referred as published sequences)²³. The newly generated HIV-1 *pol* sequences 7 (approximately 1020 nucleotides, HXB2 [K03455] positions 2267-3287) were processed from blood 8 plasma as previously described²⁴. These samples were obtained through the MSM Health Research 9 Consortium – a multi-site collaboration between the KEMRI-Wellcome Trust Research programme 10 (KWTRP) in Coastal Kenya^{25,26}, Nyanza Reproductive Health Society (NRHS) in Western Kenya²⁷, 11 Sex Workers Outreach Program (SWOP) clinics in Nairobi, Kenya and the TRANSFORM MSM 12 cohort from Nairobi, Kenya²⁸, and from the national HIV-1 reference laboratory at the KEMRI-13 CGHR in Kisumu, Kenya. Samples identified between 2006-2011 were collected under IAVI's 14 Protocol C, a study of incident HIV infection among higher risk persons; this included teams in 15 Nairobi and KWRTP²⁹. The published Kenyan HIV-1 *pol* sequences (corresponding to the HXB2 -16 K03455, *protease* and *reverse transcriptase* nucleotide positions 2000-4800 and *integrase* positions 17 $4230-5093$) were retrieved from the Los Alamos HIV database on March 20^{th} 2022^{23} .

18 Newly generated and published sequences were annotated with sampling date, sampling location 19 (county and province), ART status (whether treatment naïve or experienced), age, sex, and risk group 20 (MSM; PWID; FSW; children, and HET). Where demographic data were missing for published 21 sequences, information was obtained from reviewing associated literature or through direct 22 communication with study authors. Sequences from ART-experienced individuals were excluded 23 from this analysis.

24

25 **HIV-1 subtype determination**

26 Newly generated and published partial *pol* sequences from Kenya were aligned with the HIV-1 Group 27 M (subtypes A-K + Recombinants) subtype reference sequences (http://www.hiv.lanl.gov) using the 28 MAFFT algorithm in Geneious Prime 2019^{23} . Subtypes were determined by maximum-likelihood 1 (ML) phylogenetic analysis in PhyML using the general time-reversible substitution model with a 2 gamma-distributed rate variation and proportion of invariant sites $(GTR+ \Gamma 4+I)^{30}$. Branch support was 3 determined using the approximate likelihood ratio test with the Shimodaira-Hasegawa-like procedure 4 (aLRT-SH) in PhyML and aLRT-SH ≥0.90 was considered significant. The phylogeny was visualized 5 using FigTree v1.4.4 (https://github.com/rambaut/figtree/releases). Unique recombinant forms (URFs) 6 were characterised by boot-scan analysis in $SimPlot³¹⁻³³$. Subtype assignment was also compared with 7 results from the REGA subtyping tool (version 3.0).

8

9 **Characterisation of pre-treatment HIV-1 drug resistance**

10 All sequences from treatment-naïve individuals were submitted to the Stanford HIV database (HIVdb 11 Algorithm, version 8.8) for determination and interpretation of HIVDR mutations. The Calibrated 12 Population Resistance tool was used to identify pre-treatment drug resistance mutations, and the 13 results cross-referenced with the WHO list of mutations for the surveillance of transmitted ¹⁴ HIVDR^{34,35}. Mutations were grouped and presented based on drug class as follows: nucleoside reverse 15 transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease 16 inhibitors (PI) and integrase strand transfer inhibitors (INSTI) mutations.

17

18 **Phylogenetic determination of clusters and Bayesian inference**

19 HIV-1 sequences from ART-naïve individuals were grouped into the main HIV-1 subtypes observed 20 (A1, C and D). For each subtype-specific dataset, a search for related sequences was done separately 21 using the NCBI GenBank BLAST tool, with results limited to a threshold of 10 similar hits per 22 individual-specific sequence, as previously described^{21,36,37}. Reference sequences and sequences in the 23 Kenyan dataset with pre-treatment HIVDR mutations were compiled into subtype-specific 24 alignments, excluding codon positions associated with drug resistance mutations. ML phylogenies 25 were generated in PhyML using the GTR+ Γ 4+I model³⁰ and phylogenetic trees were annotated based 26 on the most dominant mutations per drug class i.e. K103N/S, Y181C/I/V, and G190A/S/E for NNRTI 27 resistance and M184V/I and T215 revs for NRTI resistance. Kenyan HIV-1 clusters were defined by 28 aLRT-SH support ≥0.9 and having ≥80% Kenyan sequences, and then further classified by number of

1 sequences into dyads (2 sequences), networks (3-14) sequences, and large clusters (>14 2 sequences)^{21,36,37}.

3 Dating of clusters were performed in BEAST (version 1.10.4) using the GTR+Γ4+Ι substitution 4 model, an uncorrelated lognormal relaxed clock under a Skygrid coalescent tree prior, and specifying 5 a hierarchical phylogenetic model (HPM) to enhance precision in estimating evolutionary 6 parameters^{38,39}. Cluster growth rates were inferred under a logistic growth model⁴⁰⁻⁴². BEAST runs of 300 million generations were computed, sampling every 30,000th iteration, and discarding the first 8 10% as chain burn-in. Convergence was determined in Tracer v.1.7.0 (defined as effective sample 9 sizes (ESS) ≥ 100 ³⁸. Maximum clade credibility (MCC) trees were summarized from the posterior 10 tree distribution using Tree-Annotator v1.10.4 (BEAST suite) and visualized using Figtree (v1.4.4, 11 available at: https://github.com/rambaut/figtree/releases). The basic reproductive number $(R_0, \text{ defined})$ 12 as the number of secondary infections that arise from a typical primary case in a completely 13 susceptible population) per cluster was estimated based on the respective cluster growth rate (*r*) using 14 the formula $R_0 \Box = \Box rD + 1$ (where D represents the average duration of infectiousness for individuals) 15 . $40-42$. In the absence of empiric data on the duration of infectiousness in our setting, we assumed D to 16 be one year.

17

18 **Statistical analysis**

19 Sequences were categorized by year of sampling and calendar period collapsed into five-year intervals 20 to reflect major changes in treatment guidelines in Kenya as follows: before 2005 (before introduction 21 of combination ART [cART]), 2005-2010 (introduction of cART), 2011-2015 (scale up of cART), 22 and 2016-2020 (introduction of INSTI-based regimen). Categorical data were compared with the γ^2 23 test and continuous data with the Kruskal-Wallis test where appropriate. Overall, drug-class-specific, 24 and mutation-specific HIVDR prevalence estimates and 95% confidence interval (CI) were presented. 25 HIVDR temporal trends were assessed using *nptrends*, a nonparametric extension of the Wilcoxon 26 . rank-sum test⁴³. Multivariable logistic regression models were used to determine associations between 27 risk groups, geographic locations, sampling period and pre-treatment HIVDR. All statistical tests were

- 1 2-tailed (P<0.05). Data analysis and summary plots were done using Stata 15 (StataCorp LLC,
- 2 College Station, Texas, USA) and RStudio (version 1.2.5001) with the *ggplot2* package⁴⁴.

3

4 **Nucleotide sequence accession numbers**

- 5 Newly generated nucleotide sequences are available from GenBank under the accession numbers
- 6 OM109695-OM110282.
- 7

8 **Ethical consideration**

9 For the newly generated sequences, informed consent for use of data and samples for research studies

- 10 was obtained from participants under respective study protocols. Since published sequences were
- 11 obtained from an open access repository, informed consent was not retrospectively obtained. Instead,
- 12 science and ethics approval were obtained from the Kenya Medical Research Institute (KEMRI)
- 13 Scientific and Ethics Review Unit (SERU 3547). All newly generated and published sequences were
- 14 de-identified at source before inclusion in the current analysis.

1 **RESULTS**

2

3 **Study population**

4 Overall, 5572 HIV-1 *pol* sequences (n=755 newly generated, and n=4817 published) sampled 5 between 1986-2020 were considered. Sequences from ART-experienced individuals (n=1778) and 6 those with unverified treatment status $(n=227)$ were excluded from the analysis (Figure 1). The 7 analysed dataset comprised 3567 HIV-1 sequences from ART-naïve individuals covering the reverse 8 transcriptase (n=3567, 100.0%), protease (n=2491, 69.8%) and integrase (n=106, 3.0%) coding 9 regions. Most sequences were from the HET population (n=2947, 82.1%) and from the former 10 Nairobi (n=1479, 41.5%) and Coast (n=1027, 28.8%) provinces (Table 1). The most common 11 circulating strain was HIV-1 sub-subtype A1 (n=2282, 64.0%), followed by subtype D (n=509, 12 14.3%), unique recombinant forms (URFs, n=413, 11.6%), and subtype C (n=282, 7.9%), with this 13 distribution being mostly similar across risk groups (Table 2).

14

15 **Prevalence of pre-treatment HIV-1 drug resistance**

16 Of 3567 sequences from ART-naïve individuals, 550 (15.4%, 95% CI: 14.2–16.6) had at least one 17 pre-treatment HIVDR mutation. NNRTI resistance mutations were most common (n=453, 12.7% 18 [95% CI: 11.6–13.8), followed by NRTI (n=232, 6.5% [95% CI: 5.7–7.4]) and PIs (n=23, 0.9% [95% 19 CI: 0.6–1.4). There were no INSTI resistance mutations observed over the analysis period, although 20 the number of sequences analysed were also limited (n=106) (Figure 2a, and Table S1). 21 Pre-treatment HIVDR mutations were most common amongst children (n=31, 41.3%), followed by 22 PWID (n=18, 31.0%), MSM (n=68, 20.0%), FSW (n=22, 15.1%) and HET (n=411, 13.9%). 23 Compared to other risk groups, children had higher pre-treatment NNRTI resistance mutations (n=29,

24 38.7%) while PWID had higher pre-treatment NRTI resistance mutations (n=18, 31.0%). Pre-

25 treatment PI resistance mutations were <1.0% in HET, FSW, and MSM. Pre-treatment PI mutations

26 were not observed in children and PWID although few sequences from these groups were analysed in

27 this study (Figure 2b, and Table S1).

1 Overall, the most common pre-treatment NNRTI, NRTI and PI drug resistance mutations were the 2 K103N/S (n=210, 5.9% of all sequences with any pre-treatment HIVDR), M184V (n=130, 3.6%) and 3 M46I/L (n=12, 0.5%), respectively (Figure 2c, and Table S2). Whilst K103N/S was the most common 4 NNRTI mutation amongst MSM, HET, FSW and PWID, the Y181C/I/V mutation was the most 5 common amongst children. The T215revs were the most common NRTI mutations amongst PWID, 6 whilst M184V/I was the most common NRTI mutation amongst children, FSW, HET and MSM 7 (Figure 2d, and Table S2).

8

9 **Temporal trends in pre-treatment HIV-1 drug resistance**

10 Overall, there was an increase in pre-treatment HIVDR from 6.9% (before 2005) to 24.2% (2016- 11 2020, $p\Box \angle 0.001$). Pre-treatment NNRTI resistance increased from 3.8% (before 2005) to 22.9% 12 (2016-2020, $p\leq 0.001$) while pre-treatment NRTI resistance increased from 4.2% (before 2005) to 13 8.1% (2016-2020, p=0.061). Pre-treatment PI resistance remained stable and below 2% throughout 14 the calendar periods (p=0.298) (Figure 3, and Table S3).

15 Amongst the HET population, overall pre-treatment HIVDR increased from 6.6% (before 2005) to 16 20.2% (2011-2015) – followed by a significant decline to 6.5% (2016-2020, $p\Box \langle 0.001, LBL$). 17 Levels of pre-treatment NNRTI and NRTI resistance also increased from 3.7% and 4.0% (before 18 2005) to 17.7% and 8.1% (2011-2015), followed by a decline to 6.5% and 3.2% (2015-2020, 19 p \Box < \Box 0.001, and p=0.079, LBL respectively). Pre-treatment PI resistance remained low at 0.0% 20 (before 2005), 1.0% (2011-2015) and 3.2% (2016-2020, p=0.839), though this was based on few 21 sequences and hence overlapping binomial confidence intervals. 22 Among MSM there was an overall increase in NNRTI and NRTI resistance between 2006-2010 and 23 2015-2020, though this did not achieve statistical significance (p=0.399, and p=0.241, LBL 24 respectively). Likewise, among FSW, NNRTI resistance also increased between 2006-2010 and 2015-

25 2020 (p=0.001, LBL). Data on PWID and children fell within one calendar year grouping (2006-2010

26 and 2011-2015, respectively), and were therefore excluded from trend analysis (Table S3).

1 **Phylogenetic clustering of sequences with shared pre-treatment HIV-1 drug resistance**

2 **mutations**

3 Overall, 491 sequences with pre-treatment HIVDR mutations were analysed, of which 377 were 4 subtype A1, subtype C (n=31), and subtype D (n=83). Cluster analysis revealed 32 clusters (size range 5 2-16) with the shared HIV-1 pre-treatment mutations K103N (n=14, 43.6% of all clusters), Y181C 6 (n=6, 18.9%), M184V (n=5, 15.6%), G190A/S (n=3, 9.4%), and T215revs (n=4, 12.5%, Table S4). 7 The clusters were dyads (n=26, 84.5%), networks (n=4, 12.5%), and large clusters (n=1, 3.0%). 8 Clusters were either risk-group exclusive i.e., HET only (n=24, 75.0%), MSM only (n=2, 6.3%), and 9 PWID only (n=1, 3.1%), or mixed clusters including HET/MSM (n=2, 6.3%), HET/FSW (n=1, 3.1%), 10 and HET/Children (n=2, 6.3%) (Table 3). 11 Bayesian dating was performed for clusters with ≥3 sequences with shared pre-treatment HIVDR 12 mutations – and included four subtype A1 clusters and one subtype D cluster (Table 4). The largest of 13 these comprised 16 MSM having the K103N mutation. This cluster had an estimated tMRCA of 2005 14 (HPD, 2000 – 2008) where the most recent sample was collected in 2017, suggesting that this lineage 15 had persisted over 12 years (growth rate = 0.1 /year and R₀=1.1) among ART naïve MSM in Kenya. 16 Another long-standing pre-treatment HIVDR cluster involved 11 PWID having the T215rev mutation 17 with an estimated tMRCA of 1999 (HPD, 1998 – 2001) where the most recent sample was collected 18 in 2010 – indicating that this lineage had persisted (growth rate = 0.38/year, R_0 =1.38) over 11 years 19 among ART-naïve PWID in Kenya. Overall, all except one pre-treatment HIVDR clusters had basic 20 reproductive number, $R_0 > 1$, indicative of onward propagation of pre-treatment HIVDR mutations 21 among untreated individuals in Kenya (Table 4).

1 **DISCUSSION**

2

3 We used HIV-1 *pol* sequence data from Kenya and spanning a period of more than three decades to 4 assess the prevalence, temporal trends, and transmission of HIV-1 pre-treatment drug resistance 5 among different risk groups in Kenya. Overall pre-treatment HIVDR prevalence was high (15.4%) – 6 and these estimates were largely a reflection of the high levels of pre-treatment NNRTI drug 7 resistance mutations. Notably, there was comparatively lower (<10%) pre-treatment NRTI drug 8 resistance and no pre-treatment INSTI resistance in the study population (based on a limited number 9 of HIV-1 *integrase* gene sequences), justifying the retention of two NRTIs – and a switch to a 10 dolutegravir based-regimen for HIV-1 treatment in Kenya⁴⁵.

11 We observed an increasing trend in pre-treatment HIVDR at a countrywide level, which was largely 12 driven by NNRTI resistance, an observation that is consistent with previous sub-national data from 13 Kenya and data from elsewhere in the global context^{12-15,46}. NNRTIs have a low genetic barrier which 14 permits outgrowth of resistant variants under sub-optimal drug pressure, and mutations may persist 15 for long durations, facilitating their onward transmission^{47,48}. Of interest, pre-treatment NNRTI and 16 NRTI resistance among HET (by far the largest risk group in this study) increased between 2005 and 17 2015 but declined between 2015 and 2020. This coincides with the nationwide transition from NNRTI 18 to INSTI-based ART regimens⁴⁵ – and suggests that the reduction of the use of NNRTI-based 19 regimens and the replacement with dolutegravir-based regimen may have abrogated emergence and 20 circulation of pre-treatment NNRTI and NRTI resistance mutations. In contrast to trends among HET, 21 pre-treatment HIVDR among FSW and MSM increased consistently through to 2015-2020. 22 Remarkably, as of 2020, ART coverage was lower among key populations: 73% in FSW, 68% in 23 PWID, and 63% in MSM, compared to 86% in the general HET population⁴⁹. This may explain the 24 higher resistance levels observed in key populations compared to HET, and requires further 25 investigation. Enhanced monitoring of INSTI resistance using contemporary sequences from both 26 HET and key populations would be prudent to inform future treatment strategies.

27 The high levels of K103N (in addition to Y181C, and G190A) mutations in this study likely reflect 28 extensive selection of these mutations in persons receiving NVP and EFV – both of which comprised

the main NNRTI options for first-line triple therapy regime historically in Kenya⁵⁰⁻⁵³. Also, we 2 observed several HIV-1 clusters with shared mutations spanning more than 10 years, indicating 3 onward propagation of HIVDR among treatment naïve individuals as new infections⁵⁴. There was 4 more frequent HIV-1 clustering of K103N strains. The largest cluster also comprised the K103N 5 mutation, indicating extensive transmission of this pre-treatment mutation in Kenya, possibly dating 6 back to the single-dose nevirapine era, as has been reported in other settings^{55,56}. All except one of the 7 clusters had a basic reproductive number of more than one, suggesting persistent NRTI and NNRTI 8 HIVDR transmissions. Assessment of these trends over the next few years is needed to determine 9 whether roll out of the more efficacious INSTI as a first line regimen will terminate circulation of 10 NNRTI resistance mutations in Kenya. Also, all clusters were risk-group specific, consistent with 11 previous reports that HIV-1 transmission in Kenya occurs mostly within risk groups, where HIV-1 12 mixing between risk groups is rare^{$21,22$}.

13 The main strength of our study was the near-national level coverage and the ability to assess for 14 temporal trends, dynamics, and transmission linkages spanning over three decades. However, the 15 main limitation relates to the distribution of sequence data across time periods and by risk group, with 16 some groups and time periods severely limited with very sparse sampling. Thus, temporal trends from 17 drug-class estimates (more so for PI and INSTI mutations) and risk-group estimates (more so for 18 children and PWID) should be interpreted with caution.

19 In conclusion, we demonstrated an increase in pre-treatment HIVDR over the last two decades, which 20 justifies the switch to INSTI-based therapy in Kenya. We also report long-standing propagation of 21 pre-treatment HIVDR mutations, but this might have been mitigated by the introduction of INSTI-22 based regimens. The switch to INSTI-based regimens may also have resulted in the abrogation of 23 NRTI and NNRTI mutations, as observed in the general HET population. Our study further 24 underscores the challenges with access to care and treatment for key populations as demonstrated with 25 increasing pre-treatment HIVDR in MSM and FSW – despite the broad nationwide introduction of 26 INSTI-based regimens. Taken together, our findings advocate for interventions for key populations 27 towards equitable access to care and treatment, and continued vigilance for pre-treatment HIVDR 28 surveillance to include INSTIs towards informing treatment options in Kenya.

1 **Acknowledgements**

2 We thank the staff affiliated with the MSM Health Research Consortium (MHRC) and the 3 International AIDS Vaccine Initiative (IAVI) for supporting studies involving key populations in 4 Kenya. This manuscript was submitted for publication with the permission from the Director of the 5 Kenya Medical Research Institute (KEMRI).

6

7 **Author contributions**

8 A.S.H., J.E and E.J.S. conceptualized, designed and provided funding for the study. E.J.S., S.M.G.,

9 J.K, L.M, F.C, M.M, K.M, G.M, M.M, O.A, L.G, A.D.S, and R.B provided samples from which new

10 sequences used in the study were generated. G.N.M and Y.S performed lab work. G.M.N performed

11 inferential analyses and produced figures and tables. M.K helped with producing figures and tables.

12 D.A, and P.M helped with data analysis. G.N.M wrote the original draft manuscript and all the

13 authors reviewed and edited the manuscript before submission.

14

15 **Competing Interests**

16 The authors declare no competing interests.

17

18 **Funding information**

19 This work was supported through the Sub-Saharan African Network for TB/HIV Research Excellence 20 (SANTHE), a DELTAS Africa Initiative [grant #DEL-15-006]. The DELTAS Africa Initiative is an 21 independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating 22 Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's 23 Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome 24 Trust [grant #107752/Z/15/Z, and #209294/Z/17/Z] and the UK government. This work was also 25 supported in part by funding from the Swedish Research Council (grants #2016-01417, and #2020- 26 06262) and the Swedish Society for Medical Research (grant #SA-2016). The views expressed in this 27 publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome 28 Trust, IAVI, Swedish Research Council, or the UK government.

1 **REFERENCES**

- 2
- 3 1 UNAIDS. Global HIV & AIDS statistics 2021, Sevariable at
https://www.unaids.org/en/resources/fact-sheet> (2021).
2 Sutcliffe, C. G., van Dijk, J. H., Bolton, C., Persaud, D. & Moss, W. J. Effectiveness of
antiretroviral 4 Sutcliffe, C. G., van Dijk, J. H., Bolton, C., Persaud, D.
antiretroviral therapy among HIV-infected children in
infectious diseases 8, 477-489 (2008). 5 Sutcliffe, C. G., van Dijk, J. H., Bolton, C., Persaud, D. & Moss, W. J. Effectiveness of
antiretroviral therapy among HIV-infected children in sub-Saharan Africa. The Lancet
infectious diseases 8, 477-489 (2008).
Palella 6 Palella Jr, F. J. *et al.* Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. *New England Journal of Medicine* 338, 853-860 (1998). infectious diseases **8**, 477-489 (2008).

8 3 Palella Jr, F. J. *et al.* Declining morbidit

19 immunodeficiency virus infection. Nev

10 4 Beyrer, C. & Pozniak, A. HIV drug resi 8 3 Palend Jr, F. J. et al. Declining morbialty and mortality among patients with advanced human
immunodeficiency virus infection. New England Journal of Medicine 338, 853-860 (1998).
Beyrer, C. & Pozniak, A. HIV drug resist 9 immunodeficiency virus infection. New England Journal of Medicine 338, 853-860 (1558).
Beyrer, C. & Pozniak, A. HIV drug resistance—an emerging threat to epidemic control. N
England Journal of Medicine 377, 1605-1607 (2017 10 Beyrer, C. & Pozniak, A. HIV drug resistance—an emerging threat to epidemic control. New

England Journal of Medicine 377, 1605-1607 (2017).

Frentz, D. et al. Patterns of transmitted HIV drug resistance in Europe vary by England Journal of Medicine **377**, 1605-1607 (2017).

12 5 Frentz, D. et al. Patterns of transmitted HIV drug r

13 PloS one **9**, e94495 (2014).

14 6 Kassaye, S. G. et al. Transmitted HIV drug resistance 125 Frentz, D. *et al.* Patterns of transmitted HIV drug resistance in Europe vary by risk group.

13 PloS one **9**, e94495 (2014).

14 6 Kassaye, S. G. *et al.* Transmitted HIV drug resistance is high and longstanding in m PloS one **9**, e94495 (2014).

14 6 Kassaye, S. G. *et al.* Transm

15 Washington, DC. Clinical Inj

16 7 Hassan, A. S. *et al.* Presenc 14 Massaye, S. G. et al. Transmitted HIV drug resistance is high and longstanding in metropolitant
Washington, DC. Clinical Infectious Diseases 63, 836-843 (2016).
Hassan, A. S. et al. Presence, persistence and effects of pre 15 Washington, DC. Clinical Injectious Diseases 63, 836-843 (2016).
Hassan, A. S. *et al.* Presence, persistence and effects of pre-trea
variants detected using next generation sequencing: A Retrosper
rural coastal Kenya. *Pl* 1677 Hassan, A. S. *et al.* Presence, persistence and effects of pre-treatment HIV-1 drug resistance
17 variants detected using next generation sequencing: A Retrospective longitudinal study from
18 rural coastal Kenya. *P* 17 rural coastal Kenya. *PloS one* 14, e0210559 (2019).
Drescher, S. M. *et al.* Treatment-naive individuals are the major source of transmitted HIV-1
drug resistance in men who have sex with men in the Swiss HIV Cohort Study 18 rural coastal Kenya. *Flos one* 14, eoz10559 (2019).
Drescher, S. M. *et al.* Treatment-naive individuals a
drug resistance in men who have sex with men
infectious diseases : an official publication of the I 198 Drescher, S. M. *et al.* Treatment-naive individuals are the major source of transmitted HIV-1
20 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. *Clinical*
21 infectious diseases : an offic 20 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Climedrical infectious diseases : an official publication of the Infectious Diseases Society of America 58,
285-294, doi:10.1093/cid/cit694 (2014) infectious diseases : an official publication of the Infectious Diseases Society of America 58,
22 285-294, doi:10.1093/cid/cit694 (2014).
23 9 Rhee, S. Y. *et al.* HIV-1 transmitted drug resistance surveillance: shifting 22 285-294, doi:10.1093/cid/cit694 (2014).
Rhee, S. Y. *et al.* HIV-1 transmitted drug resistance surveillance: shifting trends in study
design and prevalence estimates. *Journal of the International AIDS Society* 23, e25611, 23 9 Rhee, S. Y. *et al.* HIV-1 transmitted drug resistance surveillance: shifting trends in study
24 design and prevalence estimates. *Journal of the International AIDS Society* 23, e25611,
25 doi:10.1002/jia2.25611 (2020 24 doi:10.1002/jia2.25611 (2020).
doi:10.1002/jia2.25611 (2020).

25 doi:10.1002/jia2.25611 (2020).

- 1 18 18 Nduva, G. M., Nazziwa, J., Hassan, A. S., Sanders, E. J. & Esbjörnsson, J. The Role of

Phylogenetics in Discerning HIV-1 Mixing among Vulnerable Populations and Geographic

Regions in Sub-Saharan Africa: A Systematic R 2 Phylogenetics in Sub-Saharan Africa: A Systematic Review. *Viruses* 13, 1174 (2021).
Joint United Nations Programme on HIV/AIDS. *UNAIDS DATA 2020*,
<https://aids2020.unaids.org/report/> (2020). 3 Regions in Sub-Saharan Africa: A Systematic Review. Viruses 13, 1174 (2021).
Joint United Nations Programme on HIV/AIDS. UNAIDS
<https://aids2020.unaids.org/report/> (2020).
Bezemer, D. *et al.* HIV Type 1 transmission net 4 19 Joint United Nations Programme on Hiv/AiDS. OWAIDS DATA 2020,

20 ehttps://aids2020.unaids.org/report/> (2020).

20 Bezemer, D. *et al.* HIV Type 1 transmission networks among men having sex with men and heterosexuals i 5 Bezemer, D. *et al.* HIV Type 1 transmission ne
heterosexuals in Kenya. AIDS research and hun
Nduva, G. M. *et al.* HIV-1 Transmission Patterr 820 Bezemer, D. *et al.* HIV Type 1 transmission networks among men having sex with men and
121 beterosexuals in Kenya. AIDS research and human retroviruses **30**, 118-126 (2014).
121 Nduva, G. M. *et al.* HIV-1 Transmissio 7 heterosexuals in Kenya. *AIDS research and human retroviruses* **30**, 118-126 (2014).
Nduva, G. M. *et al.* HIV-1 Transmission Patterns Within and Between Risk Groups in Coastal
Kenya. *Sci Rep* 10, 6775, doi:10.1038/s41598 821 Nduva, G. M. *et al.* HIV-1 Transmission Patterns Within and Between Risk Groups in Coastal
821 Kenya. *Sci Rep* **10**, 6775, doi:10.1038/s41598-020-63731-z (2020).
822 Nduva, G. M. *et al.* Quantifying rates of HIV-1 f Kenya. *Sci Rep* **10**, 6775, doi:10.1038/s41598-020-63731-z (2020).

0 22 Nduva, G. M. *et al.* Quantifying rates of HIV-1 flow between ri

1 locations in Kenya: A country-wide phylogenetic study. *Virus evolu*

2 23 Los A 22 Nduva, G. M. *et al.* Quantifying rates of HIV-1 flow between risk groups and geographic
11 locations in Kenya: A country-wide phylogenetic study. *Virus evolution* **8**, veac016 (2022).
12 23 Los Alamos National Library 11 locations in Kenya: A country-wide phylogenetic study. *Virus evolution* **8**, veac016 (2022).
Los Alamos National Library. *HIV-1 database at the Los Alamos National Laboratory,*
<http://www.hiv.lanl.gov/> (2019).
Esbjörns 12 23 Los Alamos National Library. *HIV-1* database at the Los Alamos National Laboratory,

24 Esbjörnsson, J. *et al.* Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-

32 Esbjörnsson, J. *et al.* Frequent 13 Esbjörnsson, J. *et al.* Frequent CXCR
Stage disease-indication of an evolvi
Graham, S. M. *et al*. A Novel HIV-1 24 Esbjörnsson, J. *et al.* Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-
15 stage disease-indication of an evolving epidemic in West Africa. *Retrovirology* 7, 23 (2010).
16 25 Graham, S. M. *et al.* 15 1625 Graham, S. M. *et al.* A Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent
17 HIV Infection in Young Adults and Reduce HIV Transmission in Kenya: Protocol for a
18 Randomized Controlled Trial. *JMIR r* Graham, S. M. *et al.* A Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent
HIV Infection in Young Adults and Reduce HIV Transmission in Kenya: Protocol for a
Randomized Controlled Trial. *JMIR research pro* 17 Randomized Controlled Trial. *JMIR research protocols* **9**, e16198, doi:10.2196/16198 (2020).
Sanders, E. J. *et al.* High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads
following seroconversion amo 18 Randomized Controlled Trial. JNIR research protocols 9, e16198, doi:10.2190/16198 (2020).
Sanders, E. J. *et al.* High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads
following seroconversion among M 19 28 Sanders, E. J. et al. High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads

27, 437-446,

27 doi:10.1097/QAD.0b013e32835b0f81 (2013).

27 Kunzweiler, C. P. *et al.* Depressive Symptoms, Alcohol an 20 following seroconversion among MSM. AIDS 27, 437-446,
doi:10.1097/QAD.0b013e32835b0f81 (2013).
Kunzweiler, C. P. *et al.* Depressive Symptoms, Alcohol and Drug Use, and Physical and Sexual
Abuse Among Men Who Have Sex with 21 EMERTER, C. P. et al. Depressive Symptoms,
Abuse Among Men Who Have Sex with Mer
AIDS and behavior 22, 1517-1529, doi:10.1007 22 27 Kunzweiler, C. P. *et al.* Depressive Symptoms, Alcohol and Drug Use, and Physical and Sexual
23 Abuse Among Men Who Have Sex with Men in Kisumu, Kenya: The Anza Mapema Study.
24 AIDS and behavior 22, 1517-1529, doi: 23 AIDS and behavior **22**, 1517-1529, doi:10.1007/s10461-017-1941-0 (2018).
AIDS and behavior **22**, 1517-1529, doi:10.1007/s10461-017-1941-0 (2018).
- AIDS and behavior **22**, 1517-1529, doi:10.1007/s10461-017-1941-0 (2018).
AIDS and behavior **22**, 1517-1529, doi:10.1007/s10461-017-1941-0 (2018).

TABLES

Table 1. Distribution of newly generated and published HIV-1 *pol* sequences from antiretroviral therapy-naïve individuals in Kenya (n=3567, 1986-2020).

Abbreviations: ART, combined antiretroviral therapy; HET, presumed heterosexual i.e., men and women not reporting sex work or male same-sex behaviour; MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker.

Table 2. HIV-1 subtypes distribution within-and-between risk groups in Kenya (n=3567, 1986-2020).

Abbreviations: MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker; HET, presumed heterosexual i.e., men and women not reporting sex work or male same-sex behaviour; URF, unique recombinant forms; CRF, circulating recombinant form; ART, antiretroviral therapy.

Table 3. Characteristics of clusters (n=32) with shared pre-treatment HIVDR mutations and distributed into subtypes and risk group.

Number of clusters with the most dominant pre-treatment HIVDR mutations per drug class – i.e., NNRTI (K103N/S, Y181C/I/V, and G190A/S/E) and NRTI (M184V/I, and T215 revs). Abbreviations: MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker; HET, at-risk men and women who did not report sex work or male same-sex behaviour.

Table 4. Characteristics of clusters having ≥3 sequences (n=5) with shared pre-treatment HIVDR mutations.

Bayesian dating was restricted to 5 clusters having ≥3 sequences and with the three most dominant pre-treatment HIVDR mutation per drug class – i.e., NNRTI (K103N/S, Y181C/I/V, and G190A/S/E) and NRTI pre-treatment HIVDR mutations (M184V/I, T215 revs, and K70R/E). Abbreviations: MSM (men who have sex with men); PWID (people who inject drugs); FSW (female sex workers); HET (at-risk men and women who did not report sex work or male same-sex behaviour); TMRCA (time to the most recent common ancestor); and HPD (higher posterior density interval).

FIGURES

Figure 1. A flowchart summarising the number of HIV-1 pol sequences (1986-2020) analysed in this study. Abbreviations: ART, antiretroviral therapy; RTI, reverse-transcriptase inhibitors; PI, protease inhibitors; INSTI integrase inhibitors; MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker; HET, at-risk men and women who did not report sex work or male same-sex behaviour.

Figure 2. Distribution of pre-treatment HIV-1 drug resistance by (a) Proportion (95% CI) of ART- naive individuals with at least one HIV drug resistance mutations distributed by drug-class (for INSTI, CI is one-sided); (b) Distributed by drug class and risk group; (c) specific pretreatment HIVDR mutations distributed by drug class; and (d) the five most prevalent pre-treatment HIVDR mutations per drug class distributed by risk groups, in Kenya (n=3567, 1986-2020).

Figure 3. Temporal trends in pre-treatment HIV-1 drug resistance in different risk groups in Kenya (1986-2020). Overall trends and risk-group specific trends in pre-treatment HIV-1 drug resistance among (a) ART-naïve heterosexuals in the general population (HET), (b) men who have sex with men (MSM), and (c) female sex workers (FSW) in Kenya.

